STOCK TITAN

Arcutis (ARQT) director Amit Munshi receives RSUs and 16,667-share option grant

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Arcutis Biotherapeutics, Inc. director Amit Munshi reported equity awards tied to his service as a non-employee director. He received 5,778 Restricted Stock Units that convert into an equal number of common shares when they vest. After this grant, he holds 9,799 common shares directly.

Munshi also received a stock option for 16,667 shares of common stock at an exercise price of $21.23 per share. Both the RSUs and the option vest 100% on the earlier of the first anniversary of the June 5, 2026 grant date or immediately before the next annual meeting of stockholders, subject to continued service through the vesting date.

Positive

  • None.

Negative

  • None.
Insider Munshi Amit
Role null
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 16,667 $0.00 --
Grant/Award Common Stock 5,778 $0.00 --
Holdings After Transaction: Stock Option (right to buy) — 16,667 shares (Direct, null); Common Stock — 9,799 shares (Direct, null)
Footnotes (1)
  1. Represents Restricted Stock Units ("RSUs") granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof, which shall occur on the earlier of the first anniversary of the grant date, June 5, 2026, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date. The underlying shares subject to the option vest and become exercisable as to 100% on the earlier of the first anniversary of the grant date, June 5, 2026, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date.
RSUs granted 5,778 RSUs Granted as of 2026 annual meeting for non-employee director service
Common shares after grant 9,799 shares Total Arcutis common stock held directly after RSU award
Stock options granted 16,667 options Right to buy Arcutis common stock under new option award
Option exercise price $21.23 per share Exercise price for 16,667-share stock option grant
Option expiration June 5, 2036 Expiration date of the stock option grant
Vesting date reference June 5, 2026 First anniversary used to determine vesting for RSUs and option
Restricted Stock Units ("RSUs") financial
"Represents Restricted Stock Units ("RSUs") granted in connection with the Reporting Person's service as a non-employee director"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
non-employee director financial
"granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting"
annual meeting of stockholders financial
"as of the Company's 2026 annual meeting of stockholders"
stock option financial
"The underlying shares subject to the option vest and become exercisable as to 100%"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Munshi Amit

(Last)(First)(Middle)
C/O ARCUTIS BIOTHERAPEUTICS, INC.
3027 TOWNSGATE ROAD, SUITE 300

(Street)
WESTLAKE VILLAGE CALIFORNIA 91361

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Arcutis Biotherapeutics, Inc. [ ARQT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/05/2026A5,778(1)A$09,799D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$21.2306/05/2026A16,667 (2)06/05/2036Common Stock16,667$016,667D
Explanation of Responses:
1. Represents Restricted Stock Units ("RSUs") granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof, which shall occur on the earlier of the first anniversary of the grant date, June 5, 2026, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date.
2. The underlying shares subject to the option vest and become exercisable as to 100% on the earlier of the first anniversary of the grant date, June 5, 2026, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date.
Remarks:
/s/ Latha Vairavan, as Attorney-in-Fact for Amit Munshi06/09/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Amit Munshi acquire in this Arcutis (ARQT) Form 4 filing?

Amit Munshi received equity awards consisting of 5,778 RSUs and a stock option for 16,667 shares of Arcutis common stock. These awards were granted as compensation for his service as a non-employee director.

What is the exercise price of Amit Munshi’s new stock options in Arcutis (ARQT)?

The stock option granted to Amit Munshi has an exercise price of $21.23 per share. This means he can buy up to 16,667 Arcutis common shares at $21.23 each once the option vests and is exercisable.

When do Amit Munshi’s RSUs and stock options in Arcutis (ARQT) vest?

Both the 5,778 RSUs and the 16,667-share stock option vest 100% on the earlier of the first anniversary of the grant date, June 5, 2026, or immediately before the next annual meeting, subject to continued service.

How many Arcutis (ARQT) common shares does Amit Munshi hold after this Form 4?

Following the RSU grant, Amit Munshi directly holds 9,799 shares of Arcutis common stock. This total reflects his non-derivative common stock position after the reported acquisition in the Form 4 filing.

Are Amit Munshi’s new Arcutis (ARQT) awards part of director compensation?

Yes. The filing states the RSUs and stock option were granted in connection with Amit Munshi’s service as a non-employee director as of Arcutis’ 2026 annual meeting of stockholders, reflecting standard equity-based board compensation.